MX9203011A - Procedimiento para preparar una solucion acuosa de fragmento de factor de von willebrand alterado con cisteina y solucion terapeutica fundida mediante el mismo - Google Patents

Procedimiento para preparar una solucion acuosa de fragmento de factor de von willebrand alterado con cisteina y solucion terapeutica fundida mediante el mismo

Info

Publication number
MX9203011A
MX9203011A MX9203011A MX9203011A MX9203011A MX 9203011 A MX9203011 A MX 9203011A MX 9203011 A MX9203011 A MX 9203011A MX 9203011 A MX9203011 A MX 9203011A MX 9203011 A MX9203011 A MX 9203011A
Authority
MX
Mexico
Prior art keywords
fragment
solution
cysteine
preparing
von willebrand
Prior art date
Application number
MX9203011A
Other languages
English (en)
Inventor
David L Farb
Michael E Hrinda
Ted C K Lee
Christopher P Prior
Original Assignee
Rhone Poulenc Rorer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Int filed Critical Rhone Poulenc Rorer Int
Publication of MX9203011A publication Critical patent/MX9203011A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una solución acuosa de fragmento de factor de Von Willebrand alterado con cisteína, que está substacialmente libre y agregado y que es suceptible de utilizarse terapéuticamente para tratar trombosis y un procedimiento para tratar dicha solución, que comprende: (A) proveer una solución acuosa de fragmento y desnaturalizante; (B) purificar la solución o fragmento y desnaturalizante bajo condiciones que promueven la conversión de las formas de agregado del fragmento a las formas dimérica y/o monomérica del mismo, para proveer el fragmento purificado.
MX9203011A 1991-06-20 1992-06-19 Procedimiento para preparar una solucion acuosa de fragmento de factor de von willebrand alterado con cisteina y solucion terapeutica fundida mediante el mismo MX9203011A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71794291A 1991-06-20 1991-06-20

Publications (1)

Publication Number Publication Date
MX9203011A true MX9203011A (es) 1993-08-01

Family

ID=24884150

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9203011A MX9203011A (es) 1991-06-20 1992-06-19 Procedimiento para preparar una solucion acuosa de fragmento de factor de von willebrand alterado con cisteina y solucion terapeutica fundida mediante el mismo

Country Status (9)

Country Link
US (1) US5539086A (es)
EP (1) EP0590048B1 (es)
AT (1) ATE283864T1 (es)
AU (1) AU2253392A (es)
CA (1) CA2110585C (es)
DE (1) DE69233451T2 (es)
ES (1) ES2233924T3 (es)
MX (1) MX9203011A (es)
WO (1) WO1993000107A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316757A (en) * 1984-10-18 1994-05-31 Board Of Regents, The University Of Texas System Synthesis of polyazamacrocycles with more than one type of side-chain chelating groups
US5849536A (en) * 1990-03-02 1998-12-15 Bio-Technology General Corp. Cloning and production of human von willebrand factor GPIb binding domain polypeptides and methods of using same
US5847086A (en) * 1991-06-20 1998-12-08 Centeon L.L.C. Therapeutic fragments of von Willebrand factor
US6821943B2 (en) 2001-03-13 2004-11-23 S. C. Johnson & Son, Inc. Hard surface antimicrobial cleaner with residual antimicrobial effect comprising an organosilane
AU2003223936A1 (en) * 2002-05-17 2003-12-02 Kobenhavns Universitet Method for purifying denatured proteins having a desired disulfide bond configuration
CA2579374A1 (en) 2004-09-07 2006-03-30 Archemix Corp. Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
US20070066551A1 (en) * 2004-09-07 2007-03-22 Keefe Anthony D Aptamer medicinal chemistry
US20090203766A1 (en) * 2007-06-01 2009-08-13 Archemix Corp. vWF aptamer formulations and methods for use
AU2014202595A1 (en) * 2007-12-28 2014-06-05 Baxalta GmbH Recombinant VWF Formulations
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
CN101952016A (zh) * 2007-12-28 2011-01-19 巴克斯特国际公司 重组vwf配方
AU2009307648C1 (en) * 2008-10-21 2016-12-08 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
JP5876416B2 (ja) * 2009-11-13 2016-03-02 グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． フォンウィルブランド因子（ｖＷＦ）含有調製品並びにこれに関連する方法、キット及び使用
AU2016204172A1 (en) * 2016-06-20 2018-01-18 The University Of Sydney Allosteric regulation of haemostatic activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403473D0 (en) * 1984-02-09 1984-03-14 Special Trustees For St Thomas Purification of factor viii
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
EP0255206B1 (en) * 1986-05-30 1995-03-22 The Scripps Research Institute Peptides that inhibit von Willebrand factor binding
US5043429B1 (en) * 1987-05-01 1997-10-14 Scripps Research Inst Protein fragments containing factor VIII binding domain of von willebrand factor
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
US5530100A (en) * 1990-05-07 1996-06-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods for purification of recombinantly produced proteins

Also Published As

Publication number Publication date
WO1993000107A1 (en) 1993-01-07
ATE283864T1 (de) 2004-12-15
DE69233451T2 (de) 2006-01-12
CA2110585A1 (en) 1993-01-07
DE69233451D1 (de) 2005-01-05
EP0590048A4 (en) 1994-06-08
ES2233924T3 (es) 2005-06-16
US5539086A (en) 1996-07-23
EP0590048A1 (en) 1994-04-06
CA2110585C (en) 2004-10-12
EP0590048B1 (en) 2004-12-01
AU2253392A (en) 1993-01-25

Similar Documents

Publication Publication Date Title
MX9203011A (es) Procedimiento para preparar una solucion acuosa de fragmento de factor de von willebrand alterado con cisteina y solucion terapeutica fundida mediante el mismo
YU159291A (sh) Analozi azota sa kondenzovanim prstenom koji sadrže nearomatske heterocikle
MY103892A (en) Interleukin-2 of high purity production and use
DK450785D0 (da) Fremgangsmaade til fremstilling af et koncentrat af antihaemofilisk faktor med hoej renhed
SE9402595L (sv) Förfarande för kristallisation av iopamidol
ES8504255A1 (es) Procedimiento para la produccion de una hormona de crecimiento de porcino.
FI885807A (fi) Puhdistetun, biologisesti aktiivisen, bakteerien avulla tuotetun rekombinanttisen ihmis- CSF-1:n tuottaminen
ATE63750T1 (de) Peptid, dessen herstellung und benutzung.
MX9302279A (es) Metodo para la produccion del factor viii presenteen el plasma, altamente purificado.
FR2689503B1 (fr) Procede d'epuration d'un hydrofluoroalcane.
DE69637464D1 (de) Therapeutische fragmente des "von willebrand" faktors
GB8414354D0 (en) Purifying protein
FI953507A (fi) Katalyyttejä, joissa aktiiviset komponentit ovat hyvin hienojakoisina
FR2610633B1 (fr) Procede d'obtention d'un concentre d'a 1-antitrypsine a partir de plasma humain et son utilisation a titre de medicament
IT1254635B (it) Processo per la separazione degli stereoisomeri dell'acido folinico
ATE167804T1 (de) Verwendung von nickel und bromide ionen für die behandlung von psoriasis
DE68903907T2 (de) Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
FR2388824A1 (fr) 3,1-s-a2-glycoproteine riche en leucine, son procede de preparation et son utilisation
DE3680770D1 (de) Ausgangsprodukte zur herstellung von 9-beta-chlorprostaglandinen.
BG90414A (bg) 2-азабицикло (2,2,1)-хепт-5- ен-2-оцетна киселина и нейни производни, метод за получаване и приложението им
SE7906137L (sv) Rening av faktor viii
JPS529700A (en) Manufacturing method of high purity caustic soda solution
ATE24834T1 (de) Verwendung von beta-(1-adamantyl)-alpha, alphadimethylethylamin zur herstellung eines arzneimittels zur behandlung von otitis externa bei hunden.
ATE86526T1 (de) Verfahren zur herstellung von zeolith y.
MC1627A1 (fr) Procede de production d'un interferon immun

Legal Events

Date Code Title Description
GB Transfer or rights
HC Change of company name or juridical status
HC Change of company name or juridical status
FG Grant or registration